Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDER phase II trial of JDQ443 for KRAS G12C-positive non-small cell lung cancer with brain metastases
NL-OMON60427Phase 2Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of opnurasib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Maastricht University Medical Center+. Primary endpoint: Brain metastases objective response rate. Started Nov 2023; status: completed.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60427.